US7964192B1
(en)
|
1997-12-02 |
2011-06-21 |
Janssen Alzheimer Immunotherapy |
Prevention and treatment of amyloidgenic disease
|
TWI239847B
(en)
|
1997-12-02 |
2005-09-21 |
Elan Pharm Inc |
N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
|
US20080050367A1
(en)
|
1998-04-07 |
2008-02-28 |
Guriq Basi |
Humanized antibodies that recognize beta amyloid peptide
|
US7790856B2
(en)
|
1998-04-07 |
2010-09-07 |
Janssen Alzheimer Immunotherapy |
Humanized antibodies that recognize beta amyloid peptide
|
US8703126B2
(en)
|
2000-10-12 |
2014-04-22 |
Genentech, Inc. |
Reduced-viscosity concentrated protein formulations
|
ES2332402T5
(es)
*
|
2000-10-12 |
2018-05-14 |
Genentech, Inc. |
Formulaciones de proteína concentradas de viscosidad reducida
|
US7700751B2
(en)
|
2000-12-06 |
2010-04-20 |
Janssen Alzheimer Immunotherapy |
Humanized antibodies that recognize β-amyloid peptide
|
JP5290489B2
(ja)
*
|
2001-11-08 |
2013-09-18 |
アッヴィ・バイオセラピューティクス・インコーポレイテッド |
Igg抗体の安定な液体医薬製剤
|
US20070148171A1
(en)
*
|
2002-09-27 |
2007-06-28 |
Xencor, Inc. |
Optimized anti-CD30 antibodies
|
MY139983A
(en)
|
2002-03-12 |
2009-11-30 |
Janssen Alzheimer Immunotherap |
Humanized antibodies that recognize beta amyloid peptide
|
US20040002451A1
(en)
*
|
2002-06-20 |
2004-01-01 |
Bruce Kerwin |
Compositions of pegylated soluble tumor necrosis factor receptors and methods of preparing
|
EP1551875A4
(en)
*
|
2002-06-21 |
2006-06-28 |
Biogen Idec Inc |
TAMPON PREPARATIONS FOR CONCENTRATING ANTIBODIES AND METHODS FOR USE THEREOF
|
US20040033228A1
(en)
*
|
2002-08-16 |
2004-02-19 |
Hans-Juergen Krause |
Formulation of human antibodies for treating TNF-alpha associated disorders
|
MY150740A
(en)
*
|
2002-10-24 |
2014-02-28 |
Abbvie Biotechnology Ltd |
Low dose methods for treating disorders in which tnf? activity is detrimental
|
AU2003293543A1
(en)
*
|
2002-12-13 |
2004-07-09 |
Abgenix, Inc. |
System and method for stabilizing antibodies with histidine
|
US20040208870A1
(en)
*
|
2003-01-30 |
2004-10-21 |
Medimmune, Inc. |
Stabilized high concentration anti-integrin alphanubeta3 antibody formulations
|
US20040208869A1
(en)
*
|
2003-01-30 |
2004-10-21 |
Medimmune, Inc. |
Uses of anti-integrin alphanubeta3 antibody formulations
|
KR101235507B1
(ko)
*
|
2003-02-28 |
2013-02-20 |
추가이 세이야쿠 가부시키가이샤 |
단백질을 함유하는 안정화 제제
|
US20050158303A1
(en)
*
|
2003-04-04 |
2005-07-21 |
Genentech, Inc. |
Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations
|
CN1798575A
(zh)
|
2003-04-04 |
2006-07-05 |
健泰科生物技术公司 |
高浓度抗体和蛋白制剂
|
PE20050627A1
(es)
|
2003-05-30 |
2005-08-10 |
Wyeth Corp |
Anticuerpos humanizados que reconocen el peptido beta amiloideo
|
CA2544532C
(en)
*
|
2003-11-28 |
2015-06-16 |
Micromet Ag |
Compositions comprising polypeptides
|
US20050136055A1
(en)
*
|
2003-12-22 |
2005-06-23 |
Pfizer Inc |
CD40 antibody formulation and methods
|
NL1027975C2
(nl)
*
|
2004-01-09 |
2005-12-23 |
Pfizer |
Antilichamen tegen MAdCAM.
|
US20060008415A1
(en)
*
|
2004-06-25 |
2006-01-12 |
Protein Design Labs, Inc. |
Stable liquid and lyophilized formulation of proteins
|
JO3000B1
(ar)
*
|
2004-10-20 |
2016-09-05 |
Genentech Inc |
مركبات أجسام مضادة .
|
US8916165B2
(en)
|
2004-12-15 |
2014-12-23 |
Janssen Alzheimer Immunotherapy |
Humanized Aβ antibodies for use in improving cognition
|
TW200638943A
(en)
*
|
2005-01-28 |
2006-11-16 |
Wyeth Corp |
Stabilized liquid polypeptide formulations
|
GT200600031A
(es)
|
2005-01-28 |
2006-08-29 |
|
Formulacion anticuerpo anti a beta
|
AU2014240252B2
(en)
*
|
2005-03-08 |
2016-10-06 |
Pfizer Products Inc |
Anti-CTLA-4 Antibody Compositions
|
AU2012200203B2
(en)
*
|
2005-03-08 |
2014-07-03 |
Pfizer Products Inc. |
Anti-CTLA-4 Antibody Compositions
|
EP1871806A2
(en)
*
|
2005-03-08 |
2008-01-02 |
Pharmacia & Upjohn Company LLC |
ANTI-MAdCAM ANTIBODY COMPOSITIONS
|
CN101141975B
(zh)
|
2005-03-25 |
2012-05-23 |
瑞泽恩制药公司 |
Vegf拮抗剂制剂
|
JP5053264B2
(ja)
*
|
2005-05-19 |
2012-10-17 |
アムジェン インコーポレイテッド |
抗体の安定性を増加させるための組成物および方法
|
US20080311078A1
(en)
|
2005-06-14 |
2008-12-18 |
Gokarn Yatin R |
Self-Buffering Protein Formulations
|
WO2007002543A2
(en)
*
|
2005-06-23 |
2007-01-04 |
Medimmune, Inc. |
Antibody formulations having optimized aggregation and fragmentation profiles
|
JP2009502972A
(ja)
*
|
2005-07-29 |
2009-01-29 |
アムジエン・インコーポレーテツド |
タンパク質凝集を抑制する製剤
|
CA2615122A1
(en)
*
|
2005-08-03 |
2007-02-15 |
Immunogen, Inc. |
Immunoconjugate formulations
|
EA014025B1
(ru)
*
|
2005-09-12 |
2010-08-30 |
Новиммун С.А. |
Композиции антитела против cd3
|
KR101105871B1
(ko)
*
|
2005-09-27 |
2012-01-16 |
주식회사 엘지생명과학 |
인 난포자극호르몬의 안정한 용액 제형
|
EP1951757B1
(en)
|
2005-10-06 |
2014-05-14 |
Xencor, Inc. |
Optimized anti-cd30 antibodies
|
AU2006330858A1
(en)
*
|
2005-12-21 |
2007-07-05 |
Wyeth |
Protein formulations with reduced viscosity and uses thereof
|
WO2007087344A2
(en)
*
|
2006-01-25 |
2007-08-02 |
Taro Pharmaceuticals North America, Inc. |
Anti-histamine compositions and use thereof
|
AR059066A1
(es)
|
2006-01-27 |
2008-03-12 |
Amgen Inc |
Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
|
KR20140071452A
(ko)
|
2006-04-05 |
2014-06-11 |
애브비 바이오테크놀로지 리미티드 |
항체 정제
|
US9238687B2
(en)
|
2006-04-13 |
2016-01-19 |
Chugai Seiyaku Kabushiki Kaisha |
Method for recombinant production of a desired polypeptide using a mammalian cell co-expressing a taurine transporter polypeptide
|
US8784810B2
(en)
|
2006-04-18 |
2014-07-22 |
Janssen Alzheimer Immunotherapy |
Treatment of amyloidogenic diseases
|
SMP200800064B
(it)
|
2006-04-21 |
2009-11-06 |
Novartis Ag |
Composizioni farmaceutiche di anticorpi anti-cd40 antagonista
|
TW200806315A
(en)
*
|
2006-04-26 |
2008-02-01 |
Wyeth Corp |
Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
|
AU2014268186C1
(en)
*
|
2006-04-26 |
2017-12-07 |
Wyeth Llc |
Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
|
AU2016204760A1
(en)
*
|
2006-04-26 |
2016-07-28 |
Wyeth Llc |
Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
|
KR101406811B1
(ko)
|
2006-06-16 |
2014-06-12 |
리제너론 파마슈티칼스 인코포레이티드 |
유리체내 투여에 적당한 vegf 길항제 제형
|
WO2008045373A2
(en)
*
|
2006-10-06 |
2008-04-17 |
Amgen Inc. |
Stable antibody formulations
|
AU2012200284B2
(en)
*
|
2006-10-06 |
2014-03-06 |
Amgen Inc. |
Stable Antibody Formulations
|
MX2009003982A
(es)
*
|
2006-10-20 |
2009-04-27 |
Amgen Inc |
Formulaciones de polipeptido estables.
|
AU2007338791B2
(en)
*
|
2006-12-21 |
2014-03-13 |
Amgen Inc |
Stable buffered formulations containing polypeptides
|
US20100233759A1
(en)
|
2007-03-15 |
2010-09-16 |
Chugai Seiyaku Kabushiki Kaisha |
Method for production of polypeptide
|
US8003097B2
(en)
|
2007-04-18 |
2011-08-23 |
Janssen Alzheimer Immunotherapy |
Treatment of cerebral amyloid angiopathy
|
EP2173163A4
(en)
*
|
2007-07-06 |
2010-12-08 |
Glaxosmithkline Llc |
ANTIBODY FORMULATIONS
|
PL2182983T3
(pl)
|
2007-07-27 |
2014-10-31 |
Janssen Alzheimer Immunotherap |
Leczenie chorób amyloidowych z wykorzystaniem humanizowanych przeciwciał specyficznych względem Abeta
|
DK2186905T3
(en)
|
2007-08-07 |
2016-09-19 |
Chugai Pharmaceutical Co Ltd |
Method of Preparation of Heterogeneous Protein
|
WO2009041621A1
(ja)
|
2007-09-26 |
2009-04-02 |
Chugai Seiyaku Kabushiki Kaisha |
抗il-6レセプター抗体
|
PL2202245T3
(pl)
|
2007-09-26 |
2017-02-28 |
Chugai Seiyaku Kabushiki Kaisha |
Sposób modyfikowania punktu izoelektrycznego przeciwciała poprzez podstawienie aminokwasu w cdr
|
SG193868A1
(en)
|
2007-09-26 |
2013-10-30 |
Chugai Pharmaceutical Co Ltd |
Modified antibody constant region
|
RU2486245C2
(ru)
|
2007-10-15 |
2013-06-27 |
Чугаи Сейяку Кабусики Кайся |
Способ получения клетки, способной продуцировать гетеропротеины с высоким выходом
|
JO3076B1
(ar)
|
2007-10-17 |
2017-03-15 |
Janssen Alzheimer Immunotherap |
نظم العلاج المناعي المعتمد على حالة apoe
|
AU2008314973C1
(en)
|
2007-10-24 |
2014-05-08 |
Chugai Seiyaku Kabushiki Kaisha |
A cell for use in production of heteroproteins and production method using the same
|
EP3381445B1
(en)
*
|
2007-11-15 |
2023-10-25 |
Amgen Inc. |
Aqueous formulation of antibody stablised by antioxidants for parenteral administration
|
US8883146B2
(en)
|
2007-11-30 |
2014-11-11 |
Abbvie Inc. |
Protein formulations and methods of making same
|
PE20091174A1
(es)
*
|
2007-12-27 |
2009-08-03 |
Chugai Pharmaceutical Co Ltd |
Formulacion liquida con contenido de alta concentracion de anticuerpo
|
WO2009083225A2
(en)
*
|
2007-12-28 |
2009-07-09 |
Biolnvent International Ab |
Formulation
|
WO2010089522A1
(en)
*
|
2009-07-16 |
2010-08-12 |
Arecor Limited |
Stable formulation of a therapeutic protein
|
EP2328607A1
(en)
|
2008-07-16 |
2011-06-08 |
Arecor Limited |
Stable formulation of a therapeutic protein
|
ES2531385T3
(es)
|
2008-09-19 |
2015-03-13 |
Hoffmann La Roche |
Formulación que comprende un anticuerpo contra la selectina P
|
US9067981B1
(en)
|
2008-10-30 |
2015-06-30 |
Janssen Sciences Ireland Uc |
Hybrid amyloid-beta antibodies
|
RU2011126338A
(ru)
*
|
2008-11-28 |
2013-01-10 |
Эбботт Лэборетриз |
Стабильные композиции антител и способы их стабилизации
|
EP2196476A1
(en)
*
|
2008-12-10 |
2010-06-16 |
Novartis Ag |
Antibody formulation
|
US10005830B2
(en)
|
2009-03-05 |
2018-06-26 |
Ablynx N.V. |
Antigen binding dimer-complexes, methods of making/avoiding and uses thereof
|
US9265834B2
(en)
|
2009-03-05 |
2016-02-23 |
Ablynx N.V. |
Stable formulations of polypeptides and uses thereof
|
AU2010221156A1
(en)
*
|
2009-03-06 |
2011-09-22 |
Genentech, Inc. |
Antibody formulation
|
CA2749354A1
(en)
*
|
2009-03-30 |
2010-10-14 |
F. Hoffmann-La Roche Ag |
A method for avoiding glass fogging
|
US8741601B2
(en)
|
2009-04-22 |
2014-06-03 |
Chugai Seiyaku Kabushiki Kaisha |
Method for producing a cell capable of high-yield production of heteroproteins
|
JP2012526121A
(ja)
*
|
2009-05-04 |
2012-10-25 |
アボツト・バイオテクノロジー・リミテツド |
ヒト抗tnfアルファ抗体の安定した高蛋白質濃度製剤
|
US20120183531A1
(en)
*
|
2009-07-14 |
2012-07-19 |
Biogen Idee Ma Inc |
Methods for Inhibiting Yellow Color Formation in a Composition
|
WO2011026117A1
(en)
|
2009-08-31 |
2011-03-03 |
Facet Biotech Corporation |
Use of an immunoregulatory nk cell population for monitoring the efficacy of anti-il-2r antibodies in multiple sclerosis patients
|
DK2473527T3
(en)
*
|
2009-09-03 |
2017-03-06 |
Ablynx Nv |
STABLE FORMULATIONS OF POLYPEPTIDES AND APPLICATIONS THEREOF
|
US8821879B2
(en)
|
2009-09-04 |
2014-09-02 |
Xoma Technology Ltd. |
Anti-botulism antibody coformulations
|
US20110059079A1
(en)
*
|
2009-09-04 |
2011-03-10 |
Xoma Technology Ltd. |
Antibody Coformulations
|
BR112012011463A2
(pt)
|
2009-10-30 |
2017-05-02 |
Abbott Biotherapeutics Corp |
uso de populações imunorregulatórias de célula nk para prognosticar a eficácia de anticorpos anti-il-2r em pacientes com esclerose múltipla.
|
WO2011080209A2
(en)
*
|
2009-12-29 |
2011-07-07 |
F. Hoffmann-La Roche Ag |
Novel antibody formulation
|
SI2521568T1
(sl)
|
2010-01-06 |
2019-01-31 |
Dyax Corp. |
Proteini, ki vežejo plazemski kalikrein
|
US20120294866A1
(en)
*
|
2010-01-19 |
2012-11-22 |
F. Hoffmann-La Roche Ag |
Pharmaceutical formulation for proteins
|
AR080428A1
(es)
*
|
2010-01-20 |
2012-04-11 |
Chugai Pharmaceutical Co Ltd |
Formulaciones liquidas estabilizadas contentivas de anticuerpos
|
CA2976671C
(en)
|
2010-03-01 |
2021-01-12 |
Bayer Healthcare Llc |
Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
|
EP2542221A4
(en)
|
2010-03-01 |
2013-10-23 |
Cytodyn Inc |
CONCENTRATED PROTEIN FORMULATIONS AND USES THEREOF
|
AU2011262346B2
(en)
|
2010-06-04 |
2014-12-11 |
Wyeth Llc |
Streptococcus pneumoniae vaccine formulations
|
FR2961107B1
(fr)
*
|
2010-06-15 |
2012-07-27 |
Lab Francais Du Fractionnement |
Composition d'immunoglobulines humaines stabilisee
|
CN103282042B
(zh)
*
|
2010-09-17 |
2014-12-10 |
巴克斯特国际公司 |
通过具有组氨酸的水性制剂在弱酸性至中性pH稳定的免疫球蛋白
|
JO3400B1
(ar)
|
2010-09-30 |
2019-10-20 |
Ferring Bv |
مركب صيدلاني من كاربيتوسين
|
RS55161B1
(sr)
|
2010-11-04 |
2017-01-31 |
Boehringer Ingelheim Int |
Anti-il-23 antitela
|
TWI606840B
(zh)
|
2010-11-11 |
2017-12-01 |
艾伯維生物技術有限責任公司 |
具有增進高濃度之抗-TNFα抗體之液體調配物
|
EP2471554A1
(en)
*
|
2010-12-28 |
2012-07-04 |
Hexal AG |
Pharmaceutical formulation comprising a biopharmaceutical drug
|
IL269565B2
(en)
|
2011-01-06 |
2024-06-01 |
Dyax Corp |
KALLIKREIN PLASMA BINDING PROTEINS
|
KR20210030510A
(ko)
|
2011-01-13 |
2021-03-17 |
리제너론 파아마슈티컬스, 인크. |
혈관신생 눈 장애를 치료하기 위한 vegf 길항제의 용도
|
TR201810703T4
(tr)
|
2011-03-25 |
2018-08-27 |
Hoffmann La Roche |
Yeni protein saflaştırma yöntemleri.
|
UY34105A
(es)
*
|
2011-06-03 |
2012-07-31 |
Lg Life Sciences Ltd |
Formulación líquida estable de etanercept
|
AR086823A1
(es)
*
|
2011-06-30 |
2014-01-22 |
Genentech Inc |
Formulaciones de anticuerpo anti-c-met, metodos
|
EP4088736A1
(en)
|
2011-10-25 |
2022-11-16 |
Prothena Biosciences Limited |
Humanized anti-amyloid antibody formulations and methods
|
MX370199B
(es)
*
|
2012-02-16 |
2019-12-05 |
Santarus Inc |
Composiciones farmaceuticas de anticuerpo anti-antigeno muy tardio (cd49a).
|
EP2844284A1
(en)
*
|
2012-05-03 |
2015-03-11 |
Boehringer Ingelheim International GmbH |
Anti-il-23p19 antibodies
|
KR102326359B1
(ko)
|
2012-05-18 |
2021-11-12 |
제넨테크, 인크. |
고농도 모노클로날 항체 제제
|
US9216219B2
(en)
|
2012-06-12 |
2015-12-22 |
Novartis Ag |
Anti-BAFFR antibody formulation
|
CA2878508A1
(en)
*
|
2012-07-09 |
2014-01-16 |
Coherus Biosciences, Inc. |
Etanercept formulations exhibiting marked reduction in sub-visible particles
|
FR2994390B1
(fr)
|
2012-08-10 |
2014-08-15 |
Adocia |
Procede d'abaissement de la viscosite de solutions de proteines a concentration elevee
|
US8613919B1
(en)
|
2012-08-31 |
2013-12-24 |
Bayer Healthcare, Llc |
High concentration antibody and protein formulations
|
US9592297B2
(en)
|
2012-08-31 |
2017-03-14 |
Bayer Healthcare Llc |
Antibody and protein formulations
|
JP6463268B2
(ja)
*
|
2012-09-07 |
2019-01-30 |
コヒラス・バイオサイエンシズ・インコーポレイテッド |
安定水性アダリムマブ製剤
|
EP2727602A1
(en)
|
2012-10-31 |
2014-05-07 |
Takeda GmbH |
Method for preparation of a high concentration liquid formulation of an antibody
|
UA117466C2
(uk)
*
|
2012-12-13 |
2018-08-10 |
Мерк Шарп Енд Доме Корп. |
СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
|
EP2970489A2
(en)
|
2013-03-15 |
2016-01-20 |
AbbVie Biotechnology Ltd |
Anti-cd25 antibodies and their uses
|
EP3686217A1
(en)
*
|
2013-03-15 |
2020-07-29 |
GlaxoSmithKline Intellectual Property (No.2) Limited |
Low concentration antibody formulations
|
EP2970502A4
(en)
|
2013-03-15 |
2016-11-30 |
Dyax Corp |
ANTI-PLASMA KALLIKREIN ANTIBODY
|
AU2014233478A1
(en)
|
2013-03-15 |
2015-09-24 |
Abbvie Biotechnology Ltd. |
Anti-CD25 antibodies and their uses
|
CN103217525B
(zh)
*
|
2013-03-21 |
2015-04-29 |
上海执诚生物科技股份有限公司 |
一种含有提高胱抑素c胶乳包被抗体的稳定性的组合物、稳定剂及其制备方法和用途
|
KR20140119396A
(ko)
|
2013-03-29 |
2014-10-10 |
삼성전자주식회사 |
단백질 약물의 액상 제형
|
KR20220045064A
(ko)
|
2013-08-30 |
2022-04-12 |
다케다 야쿠힌 고교 가부시키가이샤 |
류마티스성 관절염의 치료에서 또는 진통제로서 사용하기 위한 gm-csf 중화 항체
|
WO2015075201A1
(en)
|
2013-11-21 |
2015-05-28 |
Genmab A/S |
Antibody-drug conjugate lyophilised formulation
|
KR20220107077A
(ko)
|
2014-01-21 |
2022-08-01 |
다케다 파머수티컬 컴패니 리미티드 |
혈장 칼리크레인 결합 단백질 및 유전성 혈관부종을 치료하는 데 있어서의 이의 용도
|
BR112016022318A2
(pt)
|
2014-03-27 |
2017-10-31 |
Dyax Corp |
método, composição farmacêutica para uso no tratamento de doenças de retina e uso de um anticorpo
|
MX2016014411A
(es)
*
|
2014-05-07 |
2017-04-06 |
Takeda Gmbh |
Formulacion liquida que comprende un compuesto neutralizante de gm-csf.
|
TWI694836B
(zh)
*
|
2014-05-16 |
2020-06-01 |
英商葛蘭素史克智慧財產管理有限公司 |
抗體調配物
|
US11357857B2
(en)
|
2014-06-20 |
2022-06-14 |
Comera Life Sciences, Inc. |
Excipient compounds for protein processing
|
US10478498B2
(en)
|
2014-06-20 |
2019-11-19 |
Reform Biologics, Llc |
Excipient compounds for biopolymer formulations
|
US20160074515A1
(en)
|
2014-06-20 |
2016-03-17 |
Reform Biologics, Llc |
Viscosity-reducing excipient compounds for protein formulations
|
SG11201609706VA
(en)
|
2014-06-23 |
2017-01-27 |
Novartis Ag |
Site specific protein modifications
|
EP3157947A1
(en)
|
2014-06-23 |
2017-04-26 |
Novartis AG |
Hsa-gdf-15 fusion polypeptide and use thereof
|
US10588980B2
(en)
|
2014-06-23 |
2020-03-17 |
Novartis Ag |
Fatty acids and their use in conjugation to biomolecules
|
EP3708679A1
(en)
|
2014-07-24 |
2020-09-16 |
Boehringer Ingelheim International GmbH |
Biomarkers useful in the treatment of il-23a related diseases
|
BR112017004169A2
(pt)
|
2014-09-03 |
2017-12-05 |
Boehringer Ingelheim Int |
composto direcionado à il-23a e ao tnf-alfa e usos do mesmo
|
SG11201703238TA
(en)
|
2014-10-24 |
2017-05-30 |
Merck Sharp & Dohme |
Co-agonists of the glucagon and glp-1 receptors
|
EP3215530B9
(en)
|
2014-11-07 |
2020-09-09 |
Sesen Bio, Inc. |
Improved il-6 antibodies
|
AR103173A1
(es)
|
2014-12-22 |
2017-04-19 |
Novarits Ag |
Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
|
KR20170103970A
(ko)
|
2015-01-23 |
2017-09-13 |
노파르티스 아게 |
개선된 반감기를 갖는 합성 아펠린 지방산 접합체
|
SG10202108996PA
(en)
|
2015-05-07 |
2021-09-29 |
Swedish Orphan Biovitrum Ag |
Methods and compositions for diagnosis and treatment of disorders in patients with elevated levels of cxcl9 and other biomarkers
|
US11091543B2
(en)
|
2015-05-07 |
2021-08-17 |
Swedish Orphan Biovitrum Ag |
Methods, compositions and dosing regimens for treating or preventing interferon-gamma related indications
|
AR104847A1
(es)
*
|
2015-06-17 |
2017-08-16 |
Lilly Co Eli |
Formulación de anticuerpo anti-cgrp
|
EP3334747B1
(en)
|
2015-08-13 |
2023-09-27 |
Amgen Inc. |
Charged depth filtration of antigen-binding proteins
|
US11229702B1
(en)
|
2015-10-28 |
2022-01-25 |
Coherus Biosciences, Inc. |
High concentration formulations of adalimumab
|
HRP20231379T1
(hr)
|
2015-12-03 |
2024-02-16 |
Regeneron Pharmaceuticals, Inc. |
Postupci dovođenja u vezu genskih varijanti s kliničkim ishodom kod pacijenata koji pate od starosne makularne degeneracije liječenih anti-vegf-om
|
WO2017096262A1
(en)
|
2015-12-04 |
2017-06-08 |
Jomoco, Corp. |
Compositions and methods to mitigate or prevent an immune response to an immunogenic therapeutic molecule in non-human primates
|
JP7003354B2
(ja)
|
2015-12-11 |
2022-03-04 |
武田薬品工業株式会社 |
遺伝性血管性浮腫の発作を治療するための血漿カリクレイン阻害薬およびその用途
|
CN108367053A
(zh)
|
2015-12-22 |
2018-08-03 |
诺华股份有限公司 |
使用生长分化因子15(gdf-15)治疗或改善代谢性疾病的方法
|
BR112018014277A2
(pt)
|
2016-01-13 |
2018-12-18 |
Genmab As |
formulação, e, método de preparação de uma solução injetável de um axl-adc
|
EP3419599A4
(en)
*
|
2016-02-23 |
2019-09-11 |
Sesen Bio, Inc. |
IL-6 ANTAGONIST FORMULATIONS AND USE THEREOF
|
US11071782B2
(en)
|
2016-04-20 |
2021-07-27 |
Coherus Biosciences, Inc. |
Method of filling a container with no headspace
|
WO2018027195A1
(en)
*
|
2016-08-05 |
2018-02-08 |
Abbvie Biotherapeutics Inc. |
Compositions containing reduced amounts of daclizumab acidic isoforms and methods for preparing the same
|
EA201990998A1
(ru)
|
2016-10-21 |
2019-11-29 |
|
Фармацевтические составы и способы их получения
|
EP3533441A4
(en)
|
2016-10-28 |
2019-12-04 |
Celltrion Inc. |
STABLE PHARMACEUTICAL FORMULATION
|
US10093731B2
(en)
|
2017-02-24 |
2018-10-09 |
Kindred Biosciences, Inc. |
Anti-IL31 antibodies for veterinary use
|
WO2018156367A1
(en)
*
|
2017-02-24 |
2018-08-30 |
Kindred Biosciences, Inc. |
Anti-il31 antibodies for veterinary use
|
GB201703062D0
(en)
*
|
2017-02-24 |
2017-04-12 |
Arecor Ltd |
Stabilized antibody protein solutions
|
US11608357B2
(en)
|
2018-08-28 |
2023-03-21 |
Arecor Limited |
Stabilized antibody protein solutions
|
TWI761453B
(zh)
|
2017-03-01 |
2022-04-21 |
英商梅迪繆思有限公司 |
抗rsv單株抗體配製物
|
EP3372242A1
(en)
|
2017-03-06 |
2018-09-12 |
Ares Trading S.A. |
Liquid pharmaceutical composition
|
EP3372241A1
(en)
|
2017-03-06 |
2018-09-12 |
Ares Trading S.A. |
Liquid pharmaceutical composition
|
KR20190129061A
(ko)
*
|
2017-03-31 |
2019-11-19 |
메이지 세이카 파루마 가부시키가이샤 |
수성 제제 및 주사기 내 수성 제제, 및 항체 단백질 탈응집제 및 항체 단백질 탈응집 방법
|
BR112019021723A2
(pt)
*
|
2017-04-18 |
2021-06-29 |
Dr. Reddy's Laboratories Limited |
formulação de anticorpo líquida estável, anticorpo na formulação, formulação líquida estável de anticorpo anti-il6r, formulação líquida estável de tocilizumab em sistema de tampão de fosfato-aminoácido, e, formulação líquida estável de tocilizumab
|
JOP20190260A1
(ar)
|
2017-05-02 |
2019-10-31 |
Merck Sharp & Dohme |
صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
|
RU2019138507A
(ru)
|
2017-05-02 |
2021-06-02 |
Мерк Шарп И Доум Корп. |
Составы антител против lag3 и совместные составы антител против lag3 и антител против pd-1
|
CN110198739B
(zh)
*
|
2017-05-16 |
2023-04-04 |
江苏恒瑞医药股份有限公司 |
一种pd-l1抗体药物组合物及其用途
|
US20190169291A1
(en)
|
2017-07-14 |
2019-06-06 |
Pfizer Inc. |
Antibodies to MAdCAM
|
BR112020004325A2
(pt)
|
2017-09-05 |
2020-10-06 |
Merck Sharp & Dohme Corp. |
compostos para reduzir a viscosidade de formulações biológicas
|
MA50174A
(fr)
*
|
2017-09-18 |
2020-07-29 |
Amgen Inc |
Formules de protéines de fusion vegfr-fc
|
CN111601613A
(zh)
|
2017-12-22 |
2020-08-28 |
诺华股份有限公司 |
用fgf21变体治疗代谢障碍的方法
|
EP4364724A2
(en)
|
2018-05-10 |
2024-05-08 |
Regeneron Pharmaceuticals, Inc. |
High concentration vegf receptor fusion protein containing formulations
|
US11519020B2
(en)
|
2018-05-25 |
2022-12-06 |
Regeneron Pharmaceuticals, Inc. |
Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF
|
CN113396158A
(zh)
|
2018-11-26 |
2021-09-14 |
诺华股份有限公司 |
Lpl-gpihbp1融合多肽
|
US20230287122A1
(en)
*
|
2018-11-29 |
2023-09-14 |
Harbour Biomed Therapeutics Limited |
Anti-pd-l1 antibody preparation
|
WO2020152367A1
(en)
|
2019-01-25 |
2020-07-30 |
Ospedale San Raffaele S.R.L. |
Inhibitor of dux4 and uses thereof
|
EP3996740A4
(en)
*
|
2019-07-12 |
2023-07-05 |
Contrafect Corporation |
THERAPEUTIC PROTEIN FORMULATIONS INCLUDING ANTIBODIES AND THEIR USES
|
GB201913697D0
(en)
|
2019-09-23 |
2019-11-06 |
King S College London |
DAP10/DAP12 fusion polypeptides
|
WO2021146336A1
(en)
*
|
2020-01-13 |
2021-07-22 |
Aptevo Research And Development Llc |
Methods and compositions for preventing adsorption of therapeutic proteins to drug delivery system components
|
GB202003277D0
(en)
|
2020-03-06 |
2020-04-22 |
King S College London |
Therapeutic agents
|
EP4153130A1
(en)
*
|
2020-05-19 |
2023-03-29 |
F. Hoffmann-La Roche AG |
The use of chelators for the prevention of visible particle formation in parenteral protein solutions
|
GB202007655D0
(en)
|
2020-05-22 |
2020-07-08 |
King S College London |
Chimeric nkg2d protein
|
CA3212856A1
(en)
|
2021-03-23 |
2022-09-29 |
John Maher |
Compositions comprising nkg2d, cxcr2, and dap10/dap12 fusion polypeptides and methods of use thereof
|
GB202214120D0
(en)
|
2022-09-27 |
2022-11-09 |
King S College London |
Compositions comprising NKG2D, CXCR2, and DAP10/DAP12 fusion polypeptides and methods of use thereof
|
EP4389762A1
(en)
|
2022-12-23 |
2024-06-26 |
Ospedale San Raffaele S.r.l. |
Inhibitors of dux4 activity and their use in therapy.
|